Advert: 728x90carrotpharmadec09
line
Menu top
Menu bottom
Website and Archive search
  Go
JobSearch
  Go
  Advert: UMAFeb2010_HouseMPU
MAGAZINE AUDIT BY
ABC Logo
Where am I? > Home > Industry News > World News
Hline
Advert: ABPIJan2010PT
LATEST WORLD NEWS Rss Feed    
Abbott Labs to buy Facet Biotech in $722 million deal
Having rejected much lower hostile bids from partner Biogen Idec last year, Facet Biotech Corp has agreed to be acquired by Abbott Laboratories for $27 per share

 Ark/Oxford BioMedica merger touted as Cerepro file is pulled
Ark Therapeutics is in talks about a possible sale after European regulators informed the UK firm that an expensive additional clinical trial is needed before its brain cancer drug Cerepro could be given the green light

 Pfizer/Biotie schizophrenia pact coming to an end
Pfizer is ending a partnership with Biotie to develop schizophrenia treatments, the Finnish drugmaker has revealed

 		FDA panel backs InterMune's Esbriet for IPF
Shares in InterMune will soar today after advisors to the US Food and Drug Administration voted in favour of recommending Esbriet for approval as a treatment for lung scarring

 FDA rejects Actelion's Zavesca for rare NP-C disease
Actelion’s bid to get a new use approved for Gaucher disease drug Zavesca has suffered a setback after regulators in the USA asked more information on the drug as a treatment for a rarer condition

 Sanofi and Merck link up to form animal health giant
As big pharma looks to sustain growth as big-selling drugs go off-patent, Sanofi-Aventis and Merck & Co have said they are combining their animal health units in a move that will create a global leader in that field
More Headlines
Arrow GSK eyes more deals in India
Arrow Germany “to break pharma price monopoly"
Arrow Exelixis cuts workforce by 40% and XenoPort halves staff
Arrow Genmab shares sink as cancer drug fails in Phase III study
Arrow After Dimebon failure, where next for Alzheimer’s?
Arrow Pfizer brings out big guns to woo Ratiopharm
Arrow Roche stops RA drug development after deaths
Arrow AstraZeneca's cediranib fails in head-to-head with Avastin
Arrow Generics set to pummel Belgian pharma market growth
Arrow Australia court says Vioxx was “unfit” for use
Arrow Court backs five-year exclusivity for Shire's ADHD drug Vyvanse
Arrow FDA pledges more industry criminal prosecutions

Older >
 
Join PharmaTimes Directors Club
Arrow Find out more
PharmaTimes Club for Directors Secretaries
Arrow Learn more
LATEST JOBS
Arrow   Clinical Nurse Advisor - Surgical & Critical Care
Arrow   BUSINESS DEVELOPMENT MANAGER - HOMECARE
Arrow   Secondary Care Representative
Arrow   Theatre Sales Representative- Theatre Consumables
Arrow   Marketing Manager
Arrow   Business Manager - Oncology
Arrow   PRODUCT MANAGER - HOMECARE
Arrow   Sales Specialist - Surgical
Arrow   Part-time Medical Representative
Arrow   Territory Manger- North-West
line
flickrtwitteryoutube